351 related articles for article (PubMed ID: 19072431)
1. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab for the treatment of Crohn's disease.
Bickston SJ; Muniyappa K
Expert Rev Clin Immunol; 2010 Jul; 6(4):513-9. PubMed ID: 20594122
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
Keeley KA; Rivey MP; Allington DR
Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
8. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
Van Assche G; Van Ranst M; Sciot R; Dubois B; Vermeire S; Noman M; Verbeeck J; Geboes K; Robberecht W; Rutgeerts P
N Engl J Med; 2005 Jul; 353(4):362-8. PubMed ID: 15947080
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of natalizumab for formulary consideration.
Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S;
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
14. [Natalizumab in the treatment of multiple sclerosis].
Horga A; Horga de la Parte JF
Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab: a promising treatment for Crohn's disease.
Colombel JF; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2006 Sep; 2(5):677-89. PubMed ID: 20477624
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
Johnson KP
Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
[TBL] [Abstract][Full Text] [Related]
17. Immunotoxicity profile of natalizumab.
Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab: new drug. Multiple sclerosis: risky market approval.
Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
Foley J
Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
